Enhabit, Inc. $EHAB Shares Sold by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Enhabit, Inc. by 10.4% in the first quarter, now owning approximately 0.66% of the company valued at nearly $2.95 million.
• Enhabit reported $0.13 EPS for the last quarter, exceeding the projected $0.10 EPS and generating revenues of $266.1 million, which also surpassed expectations.
• UBS Group downgraded Enhabit’s stock price target from $10.00 to $8.50, maintaining a "neutral" rating with an average target price set at $8.67.

Charles Schwab Investment Management Inc. lowered its stake in shares of Enhabit, Inc. (NYSE:EHAB - Free Report) by 10.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 336,072 shares of the company's stock after selling 39,044 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.66% of Enhabit worth $2,954,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in Enhabit by 295.2% during the 1st quarter. GAMMA Investing LLC now owns 3,533 shares of the company's stock valued at $31,000 after acquiring an additional 2,639 shares during the last quarter. Group One Trading LLC raised its stake in shares of Enhabit by 248.3% in the 4th quarter. Group One Trading LLC now owns 7,746 shares of the company's stock valued at $60,000 after purchasing an additional 5,522 shares in the last quarter. CWM LLC lifted its position in shares of Enhabit by 383.6% during the first quarter. CWM LLC now owns 11,738 shares of the company's stock worth $103,000 after purchasing an additional 9,311 shares during the last quarter. Boothbay Fund Management LLC bought a new position in shares of Enhabit during the fourth quarter worth about $106,000. Finally, ProShare Advisors LLC acquired a new position in Enhabit in the fourth quarter worth about $110,000.

Analysts Set New Price Targets

Separately, UBS Group cut their price objective on Enhabit from $10.00 to $8.50 and set a "neutral" rating on the stock in a research note on Friday, August 8th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $8.67.

Enhabit Stock Performance

NYSE:EHAB traded down $0.03 during midday trading on Thursday, reaching $7.84. 240,471 shares of the company traded hands, compared to its average volume of 488,239. Enhabit, Inc. has a twelve month low of $6.47 and a twelve month high of $10.90. The firm has a market capitalization of $397.16 million, a price-to-earnings ratio of -2.93 and a beta of 1.69. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.57 and a quick ratio of 1.57. The company has a fifty day moving average price of $7.45 and a 200 day moving average price of $8.46.

Enhabit (NYSE:EHAB - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.03. The company had revenue of $266.10 million for the quarter, compared to analysts' expectations of $263.39 million. Enhabit had a positive return on equity of 2.72% and a negative net margin of 12.84%. On average, analysts expect that Enhabit, Inc. will post 0.22 EPS for the current fiscal year.

Insider Transactions at Enhabit

In other news, CFO Ryan Solomon bought 10,000 shares of the firm's stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $7.64 per share, for a total transaction of $76,400.00. Following the transaction, the chief financial officer owned 193,468 shares in the company, valued at approximately $1,478,095.52. This trade represents a 5.45% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 3.40% of the stock is owned by insiders.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.